ENDOVIE: Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma
Study Details
Study Description
Brief Summary
This is a national observational retrospective multi-site chart review study of patients with advanced, recurrent or metastatic endometrial carcinoma.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Cohort 1 Patients in first line treatment (first chemotherapy for advanced, recurrent or metastatic endometrial cancer) in 2019 |
Drug: Chemotherapy
Patients with confirmed advanced, recurrent or metastatic endometrial cancer, treated by chemotherapy in real life-setting, between 1st January 2019 to 31rd December March 2019, in first or second line of chemotherapy.
|
Cohort 2 Patients in second line treatment (after one prior systemic chemotherapy) in 2019 |
Drug: Chemotherapy
Patients with confirmed advanced, recurrent or metastatic endometrial cancer, treated by chemotherapy in real life-setting, between 1st January 2019 to 31rd December March 2019, in first or second line of chemotherapy.
|
Outcome Measures
Primary Outcome Measures
- Clinical, biological and treatment characteristics [up to 3 years]
Description of the data
Secondary Outcome Measures
- Progession Free Survival real world (rwPFS) [through study completion, an average of 1 year]
From the date of initiation of the treatment in the corresponding line to the date of progression or death
- Overall Survival (OS) [through study completion, an average of 1 year]
From the date of initiation of the treatment in the corresponding line to the date of death
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Adult women ≥ 18 years at index date.
-
Documented diagnosis of advanced recurrent or metastatic endometrial cancer not eligible to primary complete surgery. Patients with interval surgery after primary CT may be eligible.
-
Index date should represent at least the first* or second line** chemotherapy systemic treatment and occur between, 1, January 2019 and 31, December 2019.
-
do not express refusal to her personal data processing or did not express her refusal for deceased patients.
Exclusion Criteria:
-
No clinical records for tumor imaging or administration of anti-cancer therapy.
-
Patients with active malignancy other than EC cancer which contribute significantly to the clinical impairment of the patient during the study period, according to investigator opinion.
-
Patients lost to follow-up, defined as patients whose last follow-up information occurs less than two years after index date (unless the patient is deceased).
-
Patient did not receive chemotherapy systemic treatment.
-
Patient undergo treatment by pembrolizumab or another immunotherapy in first line (cohort 1) or second line (cohort 2) during the eligibity (inclusion) period.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Centre Hospitalier Victor Dupouy | Argenteuil | France | 95100 | |
2 | Sainte-Catherine Institut du Cancer Avignon-Provence | Avignon | France | 84918 | |
3 | CHRU Besançon - Hôpital Jean Minjoz | Besançon | France | 25000 | |
4 | Guillaume BABIN | Bordeaux | France | 33000 | |
5 | Hôpital Morvan CHRU de Brest | Brest | France | 29200 | |
6 | Centre d'Oncologie et de Radiothérapie 37 | Chambray-lès-Tours | France | 37175 | |
7 | Hôpital Louis Mourier | Colombes | France | 92700 | |
8 | Centre Hospitalier Intercommunal de Créteil | Créteil | France | 21079 | |
9 | CHU de Dijon | Dijon | France | 21000 | |
10 | Centre Georges François Leclerc | Dijon | France | 21079 | |
11 | Groupe Hospitalier Mutualiste de Grenoble | Grenoble | France | 38028 | |
12 | Centre Oscar Lambret | Lille | France | 59020 | |
13 | Centre Léon Bérard | Lyon | France | 69737 | |
14 | ICL - Centre Alexis Vautrin | Nancy | France | 54000 | |
15 | ORACLE - Centre d'Oncologie de Gentilly | Nancy | France | 54100 | |
16 | Hôpital Privé du Confluent | Nantes | France | 44277 | |
17 | Centre Antoine Lacassagne | Nice | France | 06189 | |
18 | Centre ONCOGARD - Institut de cancérologie du Gard | Nîmes | France | 30029 | |
19 | CHR Orléans | Orléans | France | 45100 | |
20 | Institut Curie | Paris | France | 75005 | |
21 | Hôpital Cochin | Paris | France | 75014 | |
22 | Hôpital Européen Georges Pompidou | Paris | France | 75015 | |
23 | Groupe Hospitalier Diaconesses - Croix Saint-Simon | Paris | France | 75020 | |
24 | Centre CARIO - HPCA | Plérin | France | 22190 | |
25 | CHU de Poitiers - Hôpital de la Milétrie | Poitiers | France | 86021 | |
26 | Centre Eugène Marquis | Rennes | France | 35042 | |
27 | ICO - Centre René Gauducheau | Saint-Herblain | France | 44805 | |
28 | ICANS - Institut de cancérologie Strasbourg Europe | Strasbourg | France | 67033 | |
29 | CHU Tours - Hôpital Bretonneau | Tours | France | 37044 | |
30 | Gustave Roussy | Villejuif | France | 94805 |
Sponsors and Collaborators
- ARCAGY/ GINECO GROUP
- Merck Sharp & Dohme LLC
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- GINECO-EN106